Released Nov 14, 2011, during market hours
10-Q filed Nov 14, 2011, 45 days after period end · 0001019687-11-003500
Q3 2011 · 10-Q
Revenue$5.87M$5.87M −9.7% vs Q3 2010+96,638.1% vs Q2 2011
Net Income-$837.00K-$837.00K N/M vs Q3 2010N/M vs Q2 2011
EPS Diluted-$0.01-$0.01 — vs Q3 2010N/M vs Q2 2011
Operating Income-$795,000N/M
Operating Cash Flowderived-$118,000N/M
Free Cash Flowderived-$358,000—
Margins · derived
Operating margin-13.5%−15.9 pt vs Q3 2010
Net margin-14.3%−16.2 pt vs Q3 2010
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2011 | Q3 2010 |
|---|---|---|
| Revenue | $5.87M | $6.51M |
| Net Income | -$837.00K | $124.00K |
| EPS Diluted | -$0.01 | $0.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR